DiaMedica Therapeutics Inc. (DMAC) Profit Breakdown
- 2026-06-30: Single Reportable -$10.14M.
- 2025-06-30: Single Reportable -$7.70M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2017-12-31 to 2026-06-30
- Data captured
Profit by product
Net Income (Loss) Attributable to Parent: each quarter (3 month)
| Quarter end | Single Reportable |
|---|---|
| 2026-06-30 | -$10.14M |
| 2025-06-30 | -$7.70M |
Operating income: each quarter (3 month)
| Quarter end | Single Reportable |
|---|---|
| 2026-06-30 | -$10.50M |
| 2025-06-30 | -$8.01M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |